| scholarly article | Q13442814 |
| P50 | author | Maria M. Brooks | Q41533938 |
| Arshed A Quyyumi | Q88025136 | ||
| P2093 | author name string | Stephen E Epstein | |
| Nima Ghasemzadeh | |||
| Laurence Sperling | |||
| Regina Hardison | |||
| Helen Vlachos | |||
| Sergey Sikora | |||
| P2860 | cites work | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 |
| Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 | ||
| The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment | Q26830602 | ||
| Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study | Q28186001 | ||
| Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease | Q28751824 | ||
| Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes | Q33791968 | ||
| A randomized trial of therapies for type 2 diabetes and coronary artery disease | Q33827504 | ||
| Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial | Q34452976 | ||
| Role of heat shock proteins in atherosclerosis | Q34960748 | ||
| Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study | Q36455014 | ||
| Predicting the 30-year risk of cardiovascular disease: the framingham heart study | Q37356527 | ||
| Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease | Q41072972 | ||
| Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events | Q43656468 | ||
| C-reactive protein levels and outcomes after statin therapy | Q45213511 | ||
| Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). | Q46351427 | ||
| Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial | Q46489678 | ||
| Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease | Q47934879 | ||
| Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. | Q50866439 | ||
| Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease | Q57099924 | ||
| The impact of race/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial | Q61819880 | ||
| Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators | Q78017116 | ||
| Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial | Q79922447 | ||
| P433 | issue | 7 | |
| P921 | main subject | biomarker | Q864574 |
| revascularization | Q7317735 | ||
| P577 | publication date | 2017-07-03 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | An Aggregate Biomarker Risk Score Predicts High Risk of Near-Term Myocardial Infarction and Death: Findings From BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) | |
| P478 | volume | 6 |
| Q64096487 | Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study | cites work | P2860 |
Search more.